|
Cardiovascular pharmaceuticals market in India is one of the biggest therapeutic pharmaceutical markets. It is the second largest contributor to domestic sales, contributing around 15.6%.Sedentary lifestyles, hectic working schedules, increasing urbanization and high stress levels have resulted in such high number of cardiac patients in India. The report begins with the introduction section which offers a brief insight into the major cardiovascular drug classes. It then moves to the market overview section which provides an insight into the global market and then moves on to the Indian market, highlighting the market size and growth. A number of driving factors are acting as catalysts for the high growth of the industry. A detailed analysis of the drivers has been included in the next section. An analysis of the drivers explains the factors for growth of the industry including increasing patient population, patent expiry of blockbuster drugs, increase in disposable income and introduction of newer and better drugs. The key challenges include strong competition between the different pharma companies and competition from complementary and alternative medicines. The Government initiatives section highlights the different efforts on part of the Government to promote the growth of the market. These initiatives are mostly aimed at the proper distribution of drugs among all classes of patients by distributing drugs at subsidised rates at special stores, known as Jan Aushadhi stores. Various reforms in the tax structure and a cardiovascular disease control programme are the other initiatives adopted by the government. A brief overview of the drug market value chain, drug regulations and patents is presented in the next section. It analyses the pharmaceutical value chain, and focuses on the different stages of clinical trial that a drug must pass through. Drug regulations in India and drugs approved for marketing have been provided. A snapshot of different regulatory frameworks existing in the Indian pharma industry has been shown. The section also provides a list of important patent approvals for cardiovascular drugs. The competition section provides an overview of the competitive landscape in the industry. It includes a brief profile of the major players in the market along with their financials. It also includes the latest developments in the industry and it covers information such as patent approval, introduction of new drug molecules for infections treatment. The strategic recommendations section focuses on some effective strategic decisions which can be taken up by companies to increase their market shares. Foray into the preventive care therapeutic segment will help the companies gain a competitive advantage over the others. Companies can focus on development of such cardiovascular drugs which can be used as preventive medicines, but without any side effects. Also, efficient marketing strategies are required to make both the physicians and the patients aware of such preventive medicines. Research On India (ROI) is Netscribes’ leading source for market intelligence on emerging sectors in India. Our topics provide a holistic view of an industry and are a spring board for entry strategies, private equity and venture capital investments, investor presentations and management discussions. For more details on the content of the report and our services you can contact us at sales@researchonindia.com Netscribes is a market research firm that supports Market Intelligence Firm, Research & Analytics, Media & Publishing and Content Management. Netscribes services include Sales Insights, Market Intelligence, Social Media Insights, and Brand Surveillance for global clients. Netscribes (India) Pvt. Ltd. launches a report on the Cardiovascular Pharmaceuticals Market in India 2011 as part of Netscribes’ Healthcare Industry report series.
Related Articles -
Cardiovascular Pharmaceuticals Market, Cardiovascular Pharmaceuticals Market in India, Cardiovascular Pharmaceuticals Market in India 2011,
| 
